Nab-Paclitaxel Compares Favorably in Pancreatic Cost-Effectiveness Study – OncLive

OncLive
Nab-P/G is the first taxane-based therapy to show a significant improvement in overall survival (OS) in a phase III trial for patients with metastatic pancreatic cancer.1 The E/G regimen, initially approved in 2004, is among the newer options for

…read more

Source: NAB Show News From Google

Leave a Comment